Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co: Clinical Trials & FDA Approval Profile

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co (Global / Institutional) sponsors 27 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 21 active protocols (18 recruiting now), 4 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)7.4%
Median Closed Enrollment vs National (145 pts)98 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)27
Active Pipeline (Recruiting Now)21 (18)
Completed vs Stopped Early4 / 2 (7.4%)
Median Closed Actual Enrollment98 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co
Hospital Research SiteLocationShared Protocols
Jilin Cancer HospitalChangchun11
Harbin Medical University Cancer HospitalHarbin, Heilongjiang10
Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality10

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07724366A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque PsoriasisPhase IIIRECRUITING
NCT06452706The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast CancerPhase IIRECRUITING
NCT07043725A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CanPhase IIIRECRUITING
NCT07406035A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic ArthritisPhase IIRECRUITING
NCT07047365TQB2930 Injection for the Treatment of HER2-positive Advanced Breast CancerPhase IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI